Abdulla, P., Ismael, B., Namiq, K., Awrahman, Z., Sadiq, S. (2018). INSULIN-LIKE GROWTH FACTOR-1 AND BREAST CANCER RISK IN KURDISH WOMEN. Alustath, 8(1), 23-29. doi: 10.17656/jsmc.10147
Parween R. Abdulla; Bahez O. Ismael; Kadhim F. Namiq; Zmnako A. Awrahman; Shanya B. Sadiq. "INSULIN-LIKE GROWTH FACTOR-1 AND BREAST CANCER RISK IN KURDISH WOMEN". Alustath, 8, 1, 2018, 23-29. doi: 10.17656/jsmc.10147
Abdulla, P., Ismael, B., Namiq, K., Awrahman, Z., Sadiq, S. (2018). 'INSULIN-LIKE GROWTH FACTOR-1 AND BREAST CANCER RISK IN KURDISH WOMEN', Alustath, 8(1), pp. 23-29. doi: 10.17656/jsmc.10147
Abdulla, P., Ismael, B., Namiq, K., Awrahman, Z., Sadiq, S. INSULIN-LIKE GROWTH FACTOR-1 AND BREAST CANCER RISK IN KURDISH WOMEN. Alustath, 2018; 8(1): 23-29. doi: 10.17656/jsmc.10147

INSULIN-LIKE GROWTH FACTOR-1 AND BREAST CANCER RISK IN KURDISH WOMEN

JOURNAL OF SULAIMANI MEDICAL COLLEGE
Article 4, Volume 8, Issue 1, March 2018, Pages 23-29    PDF (468.93 K)
DOI: 10.17656/jsmc.10147
Authors
Parween R. Abdulla1; Bahez O. Ismael1; Kadhim F. Namiq2; Zmnako A. Awrahman1; Shanya B. Sadiq3
1Molecular Biology and Health Department, Kurdistan Institution for Strategic Studies and Scientific Research, Qirga, Sulaimani, 46001, Kurdistan-Iraq.
2Hiwa Cancer Hospital, Sulaimani, KRG, Iraq.
3Molecular Biology and Health Department, Kurdistan Institution for Strategic Studies and Scientific Research, Qirga, Sulaimani, 46001, Kurdistan-Iraq
Abstract
Background 
Insulin-like growth factor -1 (IGF-1) has mitogenic and antiapoptotic effects on breast cancer cells. High-circulating IGF-1 was found to be associated with increased risk of breast cancer in several previous epidemiological studies, mostly conducted in the Caucasian populations. Little is known about the association between IGF-1 and breast cancer in Kurdish women whose dietary habits and genetic basis differ considerably from their Caucasian counterparts. IGF-1 levels can vary substantially among individuals and have been shown to be regulated in part by diet, age, lifestyle and anthropometric indices. Nutrition and energy balance have an important influence on IGF-1 levels which are decreased in energy-restricted diets and transiently increased with intense physical activity. Despite the number of factors that can influence IGF-1 levels, it has been estimated that up to 60% of the variability has a genetic basis, also age have been shown in some studies to be an important factor. Determinants of IGF-1 levels within racial and ethnic groups are unclear.
 
Research goal 
To investigate the association between IGF-1 and breast cancer in Kurdish women. 
 
Methods
a population-based case-control study was conducted to assess the associations of IGF-1 with breast cancer risk in Kurdish women. The study included 131 incidents of premenopausal ER (+) and PR(+) breast cancer patients diagnosed between June 2016 and March 2017 at Hiwa Cancer Hospital, Slemani, Kurdistan of Iraq and 130 age-matched controls selected randomly from the general population at Marital Screening Center/ Slemani General Hospital.
 
Results
The results showed no statistically significant differences exist between the case and control in this study.
 
Conclusion
We have investigated a lack of correlation between circulating IGF-1 levels and breast cancer among Kurdish women patients.
Keywords
Insulin-like growth factor (IGF)-1; breast cancer; Case-control study; Sulaimani
References
  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebel LO M, Parkin DM, Forman D and Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: 359-386
  2. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer. 2015 Jan 15;121(2):269-75. doi: 10.1002/cncr.29041. Epub 2014 Sep 15.
  3. Sarkissyan M, Mishra DK, WU Y, Shang X, Sarkissyan S and Vadgama JV. 2011. IGF gene polymorphisms and breast cancer in African-American and Hispanic women. Int J Oncol38: 1663-1673.
  4. Sarfstein R, Pasmanik –Chor M, Yeheskel A, Edry L, Shomron N, Warman N Wertheimer E, Maor S, Shochat L and Werner H. 2012. Insulin-like Growth Factor-I Receptor (IGF-1R) translocates to nucleus and auto regulates IGF-1R gene expression in breast cancer cells. J Biol Chem 287: 2766-2776. 
  5. Christopoulos P, Msaouel Pm. and Koutsileris H. 2015. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 14: 43.
  6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–28.
  7. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 2001;85:428–30. 
  8. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008;26:4078–85
  9. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1–9. 
  10. Perks CM, Holly JM. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia. 2008; 13:455–69. 
  11. Rajah R, Lee KW, Cohen P. Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 2002;13:163–71. 
  12. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-1ndependent mechanism. J Biol Chem. 1997; 272:12181–8. 
  13. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-1, IGF-1I, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010; 19:2298–306.
  14. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum insulin-like growth factor I (IGF-1) Breast Cancer Res Treat. 1992;22:91–100. 
  15. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 2000; 88:828–32. 
  16. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G. Prospective study of IGF-1, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control. 2002; 13:307–16. 
  17. Krajcik R, Borofsky N, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-1), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11:1566–73.
  18. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, Peeters PH. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer. 2003;106:90–5
  19. Gronbaek H, Flyvbjerg A, Mellemkjaer L, Tjonneland A, Christensen J, Sorensen HT, Overvad K. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004; 13:1759–64. 
  20. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, Holly JM, Key TJ. A prospective study of serum insulin-like growth factor-I (IGF-1), IGF-1I, IGF-binding protein-3 and breast cancer risk. Br J Cancer. 2005;92:1283–7
  21. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, et al. IGF-1, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr Relat Cancer. 2006; 13:593–605. 
  22. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010; 11:530–42.
  23. Renehan A, Zwahlen M, Minder C, O'Dwyer S, Shalet S, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53. 
  24. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16:763–8. 
  25. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2008;17:1719–22. 
  26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffma B, Hood N. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat. 2002; 74:65–76.
  27. Rollison DE1, Giuliano AR, Risendal BC, Sweeney C, Boulware D, Laronga C, Baumgartner KB, Byers T, Slattery ML Serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest. Breast Cancer Res Treat. 2010 Jun;121(3):661
  28. Slattery ML1, Baumgartner KB, Byers T, Guiliano A, Sweeney C, Herrick J, Curtin K, Murtaugh M, Wolff R. Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women. Cancer Causes Control. 2005 Dec;16(10):1147-57.
  29. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol. 2008;630:148–165. 
  30. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 2006; 15:1–10. 
  31. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-1 and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer. 2006;94:299–307
  32. Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, Le Marchand L. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab. 2007;92:3660–3666
  33. Diorio C, Brisson J, Berube S, Pollak M. Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels. Cancer Epidemiol Biomarkers Prev. 2008; 17:880–888. 
  34. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) PLoS ONE. 2008; 3:e2578. 
  35. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev. 2004; 13:1290–1295.
  36. Slattery ML, Baumgartner KB, Byers T, Guiliano A, Sweeney C, Herrick J, Curtin K, Murtaugh M, Wolff R. Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women. Cancer Causes Control. 2005;16:1147–1157. 
  37. Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, Johansson M, Grobbee DE, Peeters PH, van Gils CH. Common genetic variation in the IGF-1 gene, serum IGF-1 levels and breast density. Breast Cancer Res Treat. 2008; 112:109–122. 
  38. Wagner K, Hemminki K, Forsti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat. 2007; 104:233–248. 
  39. Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006;15:1993–1997. 
  40. Rohrbacher M, Risch A, Kropp S, Chang-Claude J. The A(−336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev. 2005;14:289–290. 
  41. Setiawan VW, Cheng I, Stram DO, Penney KL, Le Marchand L, Altshuler D, Kolonel LN, Hirschhorn J, Henderson BE, Freedman ML. IGF-1 genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006;15:172–174. 
  42. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, Byers T. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat. 2007; 104:197–209. 
  43. Bernstein L, Teal CR, Joslyn S, Wilson J. Ethnicity-related variation in breast cancer risk factors. Cancer 2003; 97: 222 – 9.
Statistics
Article View: 7
PDF Download: 67


Journal Management System. Powered by ejournalplus.com